Human medicines European public assessment report (EPAR): Truxima, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Wegener Granulomatosis;Leukemia, Lymphocytic, Chronic, B-Cell;Microscopic Polyangiitis, Date of authorisation: 17/02/2017, Revision:

Human medicines European public assessment report (EPAR): Truxima, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Wegener Granulomatosis;Leukemia, Lymphocytic, Chronic, B-Cell;Microscopic Polyangiitis, Date of authorisation: 17/02/2017, Revision: 20, Status: Authorised